US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Cytosorbents Corporation - Common Stock (NQ:CTSO)

5.270 -0.740 (-12.31%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytosorbents Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
Company insiders participated in the transaction with $435,000 of investment 
From CytoSorbents
Via GlobeNewswire
News headline image
Recap: CytoSorbents Q3 Earnings ↗
 
Via Benzinga
News headline image
A Preview Of CytoSorbents's Earnings ↗
 
Via Benzinga
News headline image
Looking Into CytoSorbents's Return On Capital Employed ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data... 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Present at the 8th Annual Dawson James Conference
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival 
From CytoSorbents
Via GlobeNewswire
News headline image
Brady, America's Car-Mart And 3 Stocks To Watch Heading Into Tuesday ↗
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
Advances CytoSorb as a Potentially Revolutionary Therapeutic Advance to Reverse Deadly Shock in Critically Ill and Cardiac Surgery Patients 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Reports First Quarter 2023 Results
Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of overall sales growth in 2023 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
From CytoSorbents
Via GlobeNewswire
News headline image
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
From CytoSorbents
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >